CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Stem Cell Innovations Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Stem Cell Innovations Inc.
11222 Richmond Ave.
Suite 180
Phone: (281) 679-7900p:281 679-7900 Houston, TX  77082  United States Fax: (302) 655-5049f:302 655-5049

This company is no longer actively traded on any major stock exchange.

Business Summary
Stem Cell Innovations, Inc. has a business relating to the use of the Company's C3A human liver cell line in the field of drug discovery and toxicology testing. The Company has not yet developed any substantial market for its primary products. Stem Cell Innovations' principal revenues have been contract research and testing and consulting services for other companies, which have historically been minimal. Stem Cell Innovations intends to develop its C3A human liver cell line for the production of human serum proteins, including the clotting factors, Factor VIII and Factor IX, used by hemophiliacs to allow their blood to clot. It also intends to broaden the application of its expertise into the area of pluripotent cell biology.
(Source: 10KSB)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/200712/31/2006YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chief Executive Officer, Director James H.Kelly 56 3/1/2006 2/1/2006
Chief Scientific Officer, US IanLyons 50
Chief Scientific Officer, Europe HelmuthVan Es 49
5 additional Officers and Directors records available in full report.

Business Names
Business Name
Amphioxus Cell Technologies, Inc.
Interferon Sciences Development Corporation
Interferon Sciences, Inc.
Stem Cell Innovations, BV

General Information
Number of Employees: 21 (As of 3/31/2007)
Outstanding Shares: 1,681,137,312 (As of 6/24/2009)
Shareholders: 563
Stock Exchange: OTC
Federal Tax Id: 222313648
Fax Number: (302) 655-5049


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023